Image-Based Biomarkers in Clinical Practice

Seminars in Radiation Oncology

Volumn 21, Issue 2, 2011, Pages 157-166

  Bayouth, John E ^a   Casavant, Thomas L ^b   Graham, Michael M ^c   Sonka, Milan ^c   Muruganandham, Manickam ^a   Buatti, John M ^a  

^a UNIVERSITY OF IOWA   (United States)

^b IA United States   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18;

CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DISEASE FREE SURVIVAL; DISEASE SEVERITY; HUMAN; IMAGE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING; TREATMENT RESPONSE;

HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TUMOR MARKERS, BIOLOGICAL;

EID: 79952028437     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2010.11.003     Document Type: Review

References (46)

1. Pommier P., Dussart S., Girinsky T., et al. Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: A prospective multicenter study. Int J Radiat Oncol Biol Phys 2000, [in press].
2. Robertson V.L., Anderson C.S., Keller F.G., et al. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2010, [in press].
3. Belkacémi Y., Tsoutsou P., Magné N., et al. Metabolic functional imaging for tumor radiosensitivity monitoring. Crit Rev Oncol Hematol 2007, 62:227-239.
4. Saleem A., Charnley N., Price P. Clinical molecular imaging with positron emission tomography. Eur J Cancer 2006, 42:1720-1727.
5. Crehange G., Parfait S., Liegard M., et al. Tumor volume and metabolism of prostate cancer determined by proton magnetic resonance spectroscopic imaging at 3T without endorectal coil reveal potential clinical implications in the context of radiation oncology. Int J Radiat Oncol Biol Phys 2010, [in press].
6. Li X., Jin H., Lu Y., et al. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 2004, 17:10-20.
7. Warren K.E., Frank J.A., Black J.L., et al. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol 2000, 18:1020-1026.
8. Muruganandham M., Bayouth J.E., Smith M.C., et al. Impact of 3-Tesla MR spectroscopic imaging in the delineation of high grade glioma target volumes for radiation therapy planning. Int J Radiat Oncol Biol Phys 2008, 72:S210.
9. Alonzi R., Hoskin P. Functional imaging in clinical oncology: Magnetic resonance imaging- and computerised tomography-based techniques. Clin Oncol 2006, 18:555-570.
10. Oshida K., Nagashima T., Ueda T., et al. Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography. Eur Radiol 2005, 15:1353-1360.
11. Tuncbilek N., Karakas H.M., Okten O.O. Dynamic magnetic resonance imaging in determining histopathological prognostic factors of invasive breast cancers. Eur J Radiol 2005, 53:199-205.
12. Hawighorst H., Weikel W., Knapstein P.G., et al. Angiogenic activity of cervical carcinoma: Assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 1998, 4:2305-2312.
13. Schlemmer H.P., Merkle J., Grobholz R., et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens?. Eur Radiol 2004, 14:309-317.
14. Diergarten T., Martirosian P., Kottke R., et al. Functional characterization of prostate cancer by integrated magnetic resonance imaging and oxygenation changes during carbogen breathing. Invest Radiol 2005, 40:102-109.
15. Taylor N.J., Baddeley H., Goodchild K.A., et al. Of human tumor oxygenation during carbogen breathing. J Magn Reson Imaging 2001, 14:156-163.
16. O'Connor J.P., Naish J.H., Parker G.J., et al. Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: A potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys 2009, 75:1209-1215.
17. Habermann C.R., Gossrau P., Graessner J., et al. Diffusion-weighted echo-planar MRI: A valuable tool for differentiating primary parotid gland tumors?. Rofo 2005, 177:940-945.
18. Sato C., Naganawa S., Nakamura T., et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005, 21:258-262.
19. Hein P.A., Eskey C.J., Dunn J.F., et al. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: Tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004, 25:201-209.
20. Dzik-Jurasz A., Domenig C., George M., et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002, 360:307-308.
21. Harry V.N., Semple S.I., Gilbert F.J., et al. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008, 111:213-220.
22. Mayr N.A., Wang J.Z., Zhang D., et al. Longitudinal changes in tumor perfusion pattern during the radiation therapy course and its clinical impact in cervical cancer. Int J Radiat Oncol Biol Phys 2010, 77:502-508.
23. Schwarz J.K., Lin L.L., Siegel B.A., et al. 18-F-fluorodeoxyglucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 2008, 72:1502-1507.
24. Menda Y., Ponto L.L., Dornfeld K.J., et al. Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nucl Med Biol 2010, 37:433-438.
25. Muruganandham M., Bayouth J.E., Anderson C.M. 3D-MR spectroscopic imaging assessment of metabolic status of malignant gliomas during external beam radiation therapy-Preliminary results. Int J Radiat Oncol Biol Phys 2009, 75. S228-S2S9.
26. Ding K., Bayouth J.E., Buatti J.M., et al. 4DCT-based measurement of changes in pulmonary function following a course of radiation therapy. Med Phys 2010, 37:1261-1272.
27. Yao M., Smith R.B., Hoffman H.T., et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer: A long-term outcome report. Int J Radiat Oncol Biol Phys 2009, 74:9-14.
28. Yao M., Smith R.B., Graham M.M., et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2005, 63:991-999.
29. Kamel I.R., Bluemke D.A., Eng J., et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 2006, 17:505-512.
30. Marcus C.D., Ladam-Marcus V., Cucu C., et al. Imaging techniques to evaluate the response to treatment in oncology: Current standards and perspectives. Crit Rev Oncol/Hematol 2009, 72:217-238.
31. Price S.J., Jena R., Green H.A., et al. Early radiotherapy dose response and lack of hypersensitivity effect in normal brain tissue: A sequential dynamic susceptibility imaging study of cerebral perfusion. Clin Oncol 2007, 19:577-587.
32. National Electrical Manufacturers Association NU 2-2001 2001, NEMA.
33. Geise A.C. Technical Standards for PET/CT 2008.
34. Mawlawi OR: TG126 PET/CT Acceptance Testing and Quality Assurance.
35. Kinahan PE: TG145 quantitative imaging initiative: Quantitative PET/CT imaging.
36. Bergmann H., Dobrozemsky G., Minear G., et al. An inter-laboratory comparison study of image quality of PET scanners using the NEMA NU 2-2001 procedure for assessment of image quality. Phys Med Biol 2005, 50:2193.
37. Nichols K.J., Bacharach S.L., Bergmann S.R., et al. Instrumentation quality assurance and performance. J Nucl Cardiol 2006, 13:e25-e41.
38. Xing L. Quality Assurance of positron emission tomography/Computed Tomography for radiation therapy. Int J Radiat Oncol Biol Phys 2008, 71:S38-S42.
39. Schultheiss T.E., Boyer A.L., Horton J.L., et al. Calibration frequency as determined by analysis of machine stability. Med Phys 1989, 16:84-87.
40. Rozenfeld M., Jette D. Quality assurance of radiation dosage: Usefulness of redundancy. Radiology 1984, 150:241-244.
41. Pawlicki T., Whitaker M., Boyer A.L. Statistical process control for radiotherapy quality assurance. Med Phys 2005, 32:2777-2786.
42. Method for Evaluating QA Needs in Radiation Therapy: Task Group Report 100 American Association of Physicists in Medicine. New York, NY, American Institute of Physics (in press).
43. Balter J.M., Haffty B.G., Dunnick N.R., et al. Imaging opportunities in radiation oncology. Int J Radiat Oncol Biol Phys 2010 Aug 26, [Epub ahead of print].
44. Coleman R.E., Delbeke D., Guiberteau M.J., et al. Concurrent PET/CT with an integrated imaging system: Intersociety dialogue from the Joint Working Group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Am Coll Radiol 2005, 2:568-584.
45. Li X.A., Hendee W.R. Radiation oncology physicists will Need to better understand medical Imaging. J Am Coll Radiol 2007, 4:40-44.
46. Shortt K., Davidsson L., Hendry J., et al. International perspectives on quality assurance and new Techniques in Radiation Medicine: Outcomes of an IAEA Conference. Int J Radiat Oncol Biol Phys 2008, 71:S80-S84.